Welcome to BioSeeker Group!

Commercializing Peptides in Cancer: The Faster Route to Consider Your Options and Position of Others

Additional Information

Published Date Nov 14, 2011
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 906
PDF Fact Sheet View Fact Sheet for the report Commercializing Peptides in Cancer: The Faster Route to Consider Your Options and Position of Others in PDF
Format PDF
Publisher BioSeeker Group
Product Line View All Available Cancer Highlights Reports

Availability: In stock

$2,450.00

Quick Overview

This report will excel your competitive awareness and decrease your decision making time in managing peptide drug development in cancer.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Commercializing Peptides in Cancer: The Faster Route to Consider Your Options and Position of Others.

    To find out more about Commercializing Peptides in Cancer: The Faster Route to Consider Your Options and Position of Others, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Commercializing Peptides in Cancer: The Faster Route to Consider Your Options and Position of Others is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

This report will excel your competitive awareness and decrease your decision making time in managing peptide drug development in cancer. Find out whether you are number one, two or further down the ladder in this highly competitive market. Locate the right drugs to benchmark against and see were others may have succeeded or failed before you.

This report comprises defined and up to date development strategies for 152 peptide drugs in oncology within the portfolio of 104 companies world-wide, from Ceased to Marketed. The report extensively analyses their 123 identified drug targets, organized into 103 drug target strategies, and assesses them in 56 cancer indications. BioSeeker has applied its unique drug assessment methodology to stratify the peptide drug pipeline in oncology and discern the level of competition in fine detail.
Major Findings from this report:

* The identified competitive landscape of peptide drugs in cancer is split between the 53% which have unique drug target strategies and the other part (47%) which have head-to-head target competing peptide drugs in 22 different clusters. The latter has a competing ratio which is two times higher than the comparable average of the peptide drugs in general. Contributing to this fact is heavily utilized drug target strategies like: GNRHR and MUC1.

* Eight out of ten drug target strategies in Phase III development are new to peptide drugs in cancer and the greatest numbers of new target strategies are found in Preclinical (32%) and Phase II development (15%).

* The highest number of described target strategies among peptide drugs are found in Breast Cancer, Prostate Cancer and Pancreatic Cancer. Peptide drugs are experiencing targeting competition in only two out of every ten cancer indications described, and more so in Prostate Cancer.

* The highest number of described drug target strategies (total) of peptide drugs belongs to Cancer Research Technology (7), Affymax (4), Esperance Pharmaceuticals (3) and Raptor Pharmaceutical (3).

* From an indication perspective it is Abbott (15), Esperance Pharmaceuticals (9) and AngioChem (8) which take the lead in the widest coverage of cancer indications.

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for any peptide drug in cancer to ensure that the optimal market conditions exist by the time the product is commercialized.

1 Executive Summary 3
2 About Cancer Highlights™ 5
2.1 Cancer Focus Areas 5
2.2 Subscribe Today and Start Saving 6
2.2.1 Type of License 6
2.3 Additional Information 6
2.4 BioSeeker Group’s Oncology Team 6
3 Methodology 7
3.1 Cancer Highlights’™ Five Pillar Drug Assessment 7
4 Table of Contents 9
4.1 List of Figures 18
4.2 List of Tables 18
5 Introduction 26
5.1 The Scope of this Report 26
5.2 Definitions 29
5.3 Abbreviations 29
6 Consider the Therapeutic Target Among Peptide Drugs in Oncology for the Highest Therapeutic Outcome and Return on Investment 30
6.1 Drug Repositioning in Oncology 30
6.2 Introduction to Targets of Peptide Drugs in Oncology 31
6.2.1 Chaperone Activity Targets 36
6.2.2 Chemokine Activity Targets 39
6.2.3 Cytokine Activity Targets 44
6.2.4 Cytoskeletal Protein Binding Targets 45
6.2.5 DNA Binding Targets 46
6.2.6 DNA Binding Targets 47
6.2.7 G-protein Coupled Receptor Activity Targets 49
6.2.8 Growth Factor Activity Targets 70
6.2.9 Heat Shock Protein Activity Targets 72
6.2.10 Hormone Activity Targets 73
6.2.11 Kinase Activity Targets 74
6.2.12 Kinase Binding Targets 76
6.2.13 Kinase Regulator Activity Targets 78
6.2.14 Ligand-dependent Nuclear Receptor Activity Targets 79
6.2.15 Metallopeptidase Activity Targets 83
6.2.16 Molecular Function Unknown Targets 89
6.2.17 Oxidoreductase Activity Targets 96
6.2.18 Peptide Hormone Targets 97
6.2.19 Protease Inhibitor Activity Targets 99
6.2.20 Protein Binding Targets 100
6.2.21 Protein Serine/Threonine Kinase Activity Targets 101
6.2.22 Protein Tyrosine/Serine/Threonine Phosphatase Activity Targets 114
6.2.23 Protein-tyrosine Kinase Activity Targets 115
6.2.24 Receptor Activity Targets 118
6.2.25 Receptor Binding Targets 142
6.2.26 Receptor Signaling Complex Scaffold Activity Targets 145
6.2.27 Receptor Signaling Protein Serine/Threonine Kinase Activity Targets 149
6.2.28 RNA Binding Targets 151
6.2.29 RNA-directed DNA Polymerase Activity Targets 152
6.2.30 Serine-type Peptidase Activity Targets 154
6.2.31 Signal Transducer Activity Targets 160
6.2.32 Structural Constituent of Cytoskeleton Targets 161
6.2.33 Structural Molecule Activity Targets 162
6.2.34 T Cell Receptor Activity Targets 163
6.2.35 Transcription Factor Activity Targets 164
6.2.36 Transcription Regulator Activity Targets 175
6.2.37 Transferase Activity Targets 176
6.2.38 Transmembrane Receptor Activity Targets 178
6.2.39 Transmembrane Receptor Protein Tyrosine Kinase Activity Targets 183
6.2.40 Ubiquitin-specific Protease Activity Targets 197
6.2.41 Other Targets 199
6.3 The Cancer Genome Project and Targets of Peptide Drugs in Oncology 201
6.3.1 Targets of Peptide Drugs in Oncology Present in the Cancer Gene Census and in the Catalogue of Somatic Mutations in Cancer 201
6.4 Peptide Therapeutics is Stimulated by Available Structure Data on Biological Targets 205
6.5 Target-Target Interactions among Identified Targets of Peptide Drugs in Oncology 208
6.6 The Drug-Target Competitive Landscape 212
6.7 Protein Expression Levels of Identified Targets of Peptide Drugs in Oncology 216
6.8 Pathway Assessment of Peptide Drugs in Oncology 218
6.8.1 Tools for Analysis of Cancer Pathways 219
6.8.2 Pathway Assessment 220
7 Emerging New Products to Established Ones: Drug Target Strategies of Peptide Drugs in Oncology by their Highest Stage of Development 249
7.1 Marketed: New and Unique Drug Target Strategies of Peptide Drugs in Oncology 252
7.2 Phase III Clinical Development: New and Unique Drug Target Strategies of Peptide Drugs in Oncology 253
7.3 Phase II Clinical Development: New and Unique Drug Target Strategies of Peptide Drugs in Oncology 254
7.4 Phase I Clinical Development: New and Unique Drug Target Strategies of Peptide Drugs in Oncology 256
7.5 Preclinical Development: New and Unique Drug Target Strategies of Peptide Drugs in Oncology 258
7.6 Drug Target Strategies of Suspended or Terminated Peptide Drugs in Oncology 261
7.7 Target Strategy Development Profiles of Peptide Drugs in Oncology 264
7.7.1 Marketed 267
7.7.2 Phase III 272
7.7.3 Phase II 280
7.7.4 Phase I 296
7.7.5 Preclinical 306
7.7.6 Suspended 339
7.7.7 Ceased 341
7.8 The Competition Through Close Mechanistic Approximation of Peptide Drugs in Oncology 371
8 Selecting Subindication for Peptide Drugs in Oncology 373
8.1 Acute Myelogenous Leukemia 376
8.2 Benign Prostatic Hyperplasia 377
8.3 Biliary Cancer 378
8.4 Bladder Cancer 379
8.5 Bone Cancer 380
8.6 Brain Cancer 381
8.7 Breast Cancer 382
8.8 Cancer (general) 384
8.9 Carcinoid 385
8.10 Carcinoid Syndrome 386
8.11 Cervical Cancer 387
8.12 Chronic Lymphocytic Leukemia 388
8.13 Chronic Myelogenous Leukemia 389
8.14 Colorectal Adenoma 390
8.15 Colorectal Cancer 391
8.16 Endometrial Cancer 392
8.17 Fallopian Tube Cancer 393
8.18 Gastrointestinal Cancer (general) 394
8.19 Gastrointestinal Stomach Cancer 395
8.20 Head and Neck Cancer 396
8.21 Hematological Cancer (general) 397
8.22 Leukemia (general) 398
8.23 Liver Cancer 399
8.24 Lung Cancer (general) 401
8.25 Lymphoma (general) 402
8.26 Melanoma 403
8.27 Mesothelioma 405
8.28 Myelodysplastic Syndrome 406
8.29 Myeloma 407
8.30 Neuroblastoma 408
8.31 Neuroendocrine Cancer (general) 409
8.32 Neuroendocrine Cancer (pancreatic) 410
8.33 non-Hodgkin’s Lymphoma 411
8.34 Non-Small Cell Lung Cancer 412
8.35 Oral Cancer 414
8.36 Ovarian Cancer 415
8.37 Pancreatic Cancer 417
8.38 Peritoneal Cancer 419
8.39 Prostate Cancer 420
8.40 Radio/chemotherapy-induced Alopecia 423
8.41 Radio/chemotherapy-induced Anemia 424
8.42 Radio/chemotherapy-induced Bone Marrow Injury (general) 425
8.43 Radio/chemotherapy-induced GI Injury 426
8.44 Radio/chemotherapy-induced Injury (general) 427
8.45 Radio/chemotherapy-induced Mucositis 428
8.46 Radio/chemotherapy-induced Nausea and Vomiting 429
8.47 Radio/chemotherapy-induced Neutropenia 430
8.48 Renal Cancer 431
8.49 Sarcoma (general) 433
8.50 Skin Cancer (general) 434
8.51 Small Cell Lung Cancer 435
8.52 Soft Tissue Sarcoma 436
8.53 Solid Tumor 437
8.54 Squamous Cell Cancer 438
8.55 Unspecified Cancer Indication 439
8.56 Vaccine Adjunct 441
9 Pipeline and Portfolio Planning: Competitive Benchmarking of the Peptide Drug Pipeline in Oncology by Investigator 442
9.1 Changes in the Competitive Landscape: M&A, Bankruptcy and Name Change 445
9.2 Company Facts and Ranking 446
9.3 Competitive Fall-Out Assessment 452
9.4 7TM Pharma 454
9.5 Abbott 457
9.6 Acceleron Pharma 464
9.7 AEterna Zentaris 469
9.8 Affymax 474
9.9 Aileron Therapeutics 480
9.10 Allostera 483
9.11 Allosterix 486
9.12 Ambrilia Biopharma 490
9.13 Anchor Therapeutics 493
9.14 AngioChem 497
9.15 Angstrom Pharmaceuticals 502
9.16 AplaGen Biopharmaceuticals 506
9.17 ApopLogic Pharmaceuticals 509
9.18 Ardana 513
9.19 AstraZeneca 519
9.20 Attenuon 524
9.21 AVI BioPharma 527
9.22 Baxter International 531
9.23 Biokine Therapeutics 536
9.24 Bristol-Myers Squibb 540
9.25 CanBas 543
9.26 Cancer Advances 548
9.27 Cancer Innovations 552
9.28 Cancer Research Technology 556
9.29 CDG Therapeutics 563
9.30 Celecure 566
9.31 Celldex Therapeutics 569
9.32 Chemokine Therapeutics 573
9.33 Cleveland BioLabs 578
9.34 Clinuvel 581
9.35 Compugen 584
9.36 Curaxis 587
9.37 Cyclacel 592
9.38 Daiichi Sankyo 595
9.39 Dendreon 598
9.40 Diatos 603
9.41 Digna Biotech 608
9.42 Dongkook Pharm 611
9.43 Eli Lilly 616
9.44 Endo Pharmaceuticals 620
9.45 Enkam Pharmaceuticals 625
9.46 EntreMed 629
9.47 Esperance Pharmaceuticals 633
9.48 Galena Biopharma 640
9.49 Generex 645
9.50 GENova Biotherapeutics 648
9.51 Genovax 651
9.52 GlaxoSmithKline 656
9.53 Gliknik 661
9.54 GP Pharm 664
9.55 Gryphon Therapeutics 670
9.56 Hoffmann-La Roche 673
9.57 ImmunoCellular Therapeutics 678
9.58 Immunotope 682
9.59 ImmuPharma 686
9.60 Innovive 691
9.61 ISA Pharmaceuticals 696
9.62 Johnson & Johnson 700
9.63 Karyon-CTT 706
9.64 Lee’s Pharmaceutical 709
9.65 Marillion Pharmaceuticals 712
9.66 MBiotec 716
9.67 Meda 719
9.68 Mediolanum 724
9.69 MolMed 729
9.70 Nektar Therapeutics 733
9.71 Nemod Biotherapeutics 738
9.72 Neurobiological Technologies 743
9.73 Nidus Laboratories 746
9.74 Non-industrial source 751
9.75 Novartis 760
9.76 NPS Pharmaceuticals 765
9.77 OncoTherapy Science 768
9.78 Oncothyreon 772
9.79 Pepscan Therapeutics 778
9.80 Peptagen 782
9.81 PepTx 785
9.82 PharmaGap 789
9.83 Pharmexa 794
9.84 Protagonist 799
9.85 Q Chip 802
9.86 QLT 807
9.87 Raptor Pharmaceutical 812
9.88 Receptor BioLogix 816
9.89 Sanofi-Aventis 821
9.90 SciClone Pharmaceuticals 824
9.91 Serometrix 828
9.92 Shire 831
9.93 Soligenix 836
9.94 Spectrum Pharmaceuticals 841
9.95 Thallion Pharmaceuticals 844
9.96 Therion Biologics 848
9.97 Theryte 851
9.98 Tigris Pharmaceuticals 855
9.99 Unigene 858
9.100 United Biomedical 863
9.101 Vaxil BioTherapeutics 866
9.102 Vaxon Biotech 871
9.103 VaxOnco 876
9.104 Wilex 881
9.105 Xigen 886
9.106 Zelos Therapeutics 889
9.107 Zensun 892
10 Disclaimer 896
11 Drug Index 897
12 Company Index 902

4.1 List of Figures
Figure 1: Visualization of Target-Target Interactions among Targets of Peptide Drugs in Oncology 211
Figure 2: The Drug-Target Competitive Landscape of Peptide Drugs in Oncology - Large Cluster 213
Figure 3: The Drug-Target Competitive Landscape Peptide Drugs in Oncology - Smaller Clusters 214
Figure 4: Head-to-Head Targeting Competitive Landscape of Peptide Drugs in Oncology 215
Figure 5: Number of Companies per Ranking Level 446

4.2 List of Tables
Table 1: Cancer Highlights’™ Five Pillar Drug Assessment 7
Table 2: Breakdown of the Included Peptide Drug Pipeline in Oncology by Stage of Development 26
Table 3: Head to Head Target Competition among Peptide Drugs in Oncology 26
Table 4: Overview of Drug Target Strategy Themes 31
Table 5: Terminally Ceased Targets of Peptide Drugs in Oncology 32
Table 6: Official Gene Name to Target Profle 33
Table 7: Targets of Peptide Drugs in Oncology Present in the Catalogue of Somatic Mutations in Cancer and in the Cancer Gene Census 202
Table 8: Identity of Drug Targets with Available Biological Structures 205
Table 9: Number of Target-Target Interactions among Targets of Peptide Drugs in Oncology 209
Table 10: Available Protein Expression Profiles of Peptide Drug Targets in Oncology 216
Table 11: Pathway Summary 220
Table 12: Drug Targets without any Identified Assigned Pathways 220
Table 13: Pathway Profiles According to BioCarta of Peptide Drug Targets in Oncology 222
Table 14: Pathway Profiles According to KEGG of Peptide Drug Targets in Oncology 233
Table 15: Pathway Profiles According to NetPath of Peptide Drug Targets in Oncology 245
Table 16: Number of Drug Target Strategies by their Highest Developmental Stage and Uniqueness 249
Table 17: Top Competitive Target Strategies of Peptide Drugs in Oncology 250
Table 18: New and Unique Target Strategies of Marketed Peptide Drugs in Oncology 252
Table 19: The Competition Through Close Mechanistic Approximation Between Peptide Drugs in Oncology being Marketed or in Pre-registration 252
Table 20: New and Unique Target Strategies in Phase III Clinical Development of Peptide Drugs in Oncology 253
Table 21: The Competition Through Close Mechanistic Approximation Between Phase III Peptide Drugs in Oncology 253
Table 22: New and Unique Target Strategies in Phase II Clinical Development of Peptide Drugs in Oncology 254
Table 23: The Competition Through Close Mechanistic Approximation Between Phase II Peptide Drugs in Oncology 255
Table 24: New and Unique Target Strategies in Phase I Clinical Development of Peptide Drugs in Oncology 256
Table 25: The Competition Through Close Mechanistic Approximation Between Phase I Peptide Drugs in Oncology 257
Table 26: New and Unique Target Strategies in Preclinical Development of Peptide Drugs in Oncology 258
Table 27: The Competition Through Close Mechanistic Approximation Between Preclinical Peptide Drugs in Oncology 259
Table 28: Target Strategies of Suspended and Terminated Peptide Drugs in Oncology 261
Table 29: Connecting Target Strategy with Its Profile Identification Number 264
Table 30: The Competition Through Close Mechanistic Approximation Among Peptide Drugs in Oncology 371
Table 31 Competitive Summary by Cancer Indication of Peptide Drugs 374
Table 32: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Acute Myelogenous Leukemia 376
Table 33: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Benign Prostatic Hyperplasia 377
Table 34: The Competition through Close Mechanistic Approximation between Benign Prostatic Hyperplasia Drugs 377
Table 35: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Biliary Cancer 378
Table 36: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Bladder Cancer 379
Table 37: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Bone Cancer 380
Table 38: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Brain Cancer 381
Table 39: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Breast Cancer 382
Table 40: The Competition through Close Mechanistic Approximation between Breast Cancer Drugs 383
Table 41: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Cancer (general) 384
Table 42: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Carcinoid 385
Table 43: The Competition through Close Mechanistic Approximation between Carcinoid Drugs 385
Table 44: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Carcinoid Syndrome 386
Table 45: The Competition through Close Mechanistic Approximation between Carcinoid Syndrome Drugs 386
Table 46: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Cervical Cancer 387
Table 47: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Chronic Lymphocytic Leukemia 388
Table 48: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Chronic Myelogenous Leukemia 389
Table 49: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Colorectal Adenoma 390
Table 50: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Colorectal Cancer 391
Table 51: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Endometrial Cancer 392
Table 52: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Fallopian Tube Cancer 393
Table 53: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Gastrointestinal Cancer (general) 394
Table 54: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Gastrointestinal Stomach Cancer 395
Table 55: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Head and Neck Cancer 396
Table 56: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Hematological Cancer (general) 397
Table 57: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Leukemia (general) 398
Table 58: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Liver Cancer 399
Table 59: The Competition through Close Mechanistic Approximation between Liver Cancer Drugs 399
Table 60: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Lung Cancer (general) 401
Table 61: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Lymphoma (general) 402
Table 62: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Melanoma 403
Table 63: The Competition through Close Mechanistic Approximation between Melanoma Drugs 404
Table 64: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Mesothelioma 405
Table 65: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Myelodysplastic Syndrome 406
Table 66: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Myeloma 407
Table 67: The Competition through Close Mechanistic Approximation between Myeloma Drugs 407
Table 68: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Neuroblastoma 408
Table 69: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Neuroendocrine Cancer (general) 409
Table 70: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Neuroendocrine Cancer (pancreatic) 410
Table 71: Target Strategy Development Profiles of Peptide Drugs for the Treatment of non-Hodgkin’s Lymphoma 411
Table 72: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Non-Small Cell Lung Cancer 412
Table 73: The Competition through Close Mechanistic Approximation between Non-Small Cell Lung Cancer Drugs 413
Table 74: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Oral Cancer 414
Table 75: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Ovarian Cancer 415
Table 76: The Competition through Close Mechanistic Approximation between Ovarian Cancer Drugs 416
Table 77: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Pancreatic Cancer 417
Table 78: The Competition through Close Mechanistic Approximation between Pancreatic Cancer Drugs 418
Table 79: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Peritoneal Cancer 419
Table 80: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Prostate Cancer 420
Table 81: The Competition through Close Mechanistic Approximation between Prostate Cancer Drugs 421
Table 82: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Radio/chemotherapy-induced Alopecia 423
Table 83: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Radio/chemotherapy-induced Anemia 424
Table 84: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Radio/chemotherapy-induced Bone Marrow Injury (general) 425
Table 85: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Radio/chemotherapy-induced GI Injury 426
Table 86: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Radio/chemotherapy-induced Injury (general) 427
Table 87: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Radio/chemotherapy-induced Mucositis 428
Table 88: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Radio/chemotherapy-induced Nausea and Vomiting 429
Table 89: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Radio/chemotherapy-induced Neutropenia 430
Table 90: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Renal Cancer 431
Table 91: The Competition through Close Mechanistic Approximation between Non-Small Cell Lung Cancer Drugs 431
Table 92: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Sarcoma (general) 433
Table 93: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Skin Cancer (general) 434
Table 94: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Small Cell Lung Cancer 435
Table 95: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Soft Tissue Sarcoma 436
Table 96: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Solid Tumor 437
Table 97: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Squamous Cell Cancer 438
Table 98: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Unspecified Cancer Indication 439
Table 99: The Competition through Close Mechanistic Approximation between Unspecified Cancer Drugs 440
Table 100: Target Strategy Development Profiles of Peptide Drugs for the Treatment of Vaccine Adjunct 441
Table 101: Competitive Summary by Investigator of Peptide Drug Development 442
Table 102: Summary Table of Corporate Changes in the Competitive Landscape of Peptide Drug Development in Oncology 445
Table 103: Example of a Competitive Fall-Out Table (Targeting GNRHR/Modified) 452
Table 104: 7TM Pharma’s Included Peptide Drug Pipeline in Oncology and Competitive Fall-Out 455
Table 105: Abbott’s Included Peptide Drug Pipeline in Oncology and Competitive Fall-Out 460
Table 106: Acceleron Pharma’s Included Peptide Drug Pipeline in Oncology and Competitive Fall-Out 466
Table 107: AEterna Zentaris’Included Peptide Drug Pipeline in Oncology and Competitive Fall-Out 471
Table 108: Affymax’s Included Peptide Drug Pipeline in Oncology and Competitive Fall-Out 476
Table 109: Aileron Therapeutics’Included Peptide Drug Pipeline in Oncology and Competitive Fall-Out 481
Table 110: Allostera’s Included Peptide Drug Pipeline in Oncology and Competitive Fall-Out 484
Table 111: Allosterix’s Included Peptide Drug Pipeline in Oncology and Competitive Fall-Out 487
Table 112: Ambrilia Biopharma’s Included Peptide Drug Pipeline in Oncology and Competitive Fall-Out 491
Table 113: Anchor Therapeutics’Included Peptide Drug Pipeline in Oncology and Competitive Fall-Out 494
Table 114: AngioChem’s Included Peptide Drug Pipeline in Oncology and Competitive Fall-Out 499
Table 115: Angstrom Pharmaceuticals’Included Peptide Drug Pipeline in Oncology and Competitive Fall-Out 503
Table 116: AplaGen Biopharmaceuticals’Included Peptide Drug Pipeline in Oncology and Competitive Fall-Out 507
Table 117: ApopLogic Pharmaceuticals’Included Peptide Drug Pipeline in Oncology and Competitive Fall-Out 510
Table 118: Ardana’s Included Peptide Drug Pipeline in Oncology and Competitive Fall-Out 515
Table 119: AstraZeneca’s Included Peptide Drug Pipeline in Oncology and Competitive Fall-Out 521
Table 120: Attenuon’s Included Peptide Drug Pipeline in Oncology and Competitive Fall-Out 525
Table 121: AVI BioPharma’s Included Peptide Drug Pipeline in Oncology and Competitive Fall-Out 528
Table 122: Baxter International’s Included Peptide Drug Pipeline in Oncology and Competitive Fall-Out 533
Table 123: Biokine Therapeutics’Included Peptide Drug Pipeline in Oncology and Competitive Fall-Out 537
Table 124: Bristol-Myers Squibb’s Included Peptide Drug Pipeline in Oncology and Competitive Fall-Out 541
Table 125: CanBas’Included Peptide Drug Pipeline in Oncology and Competitive Fall-Out 545
Table 126: Cancer Advances’Included Peptide Drug Pipeline in Oncology and Competitive Fall-Out 549
Table 127: Cancer Innovations’Included Peptide Drug Pipeline in Oncology and Competitive Fall-Out 553
Table 128: Cancer Research Technology’s Included Peptide Drug Pipeline in Oncology and Competitive Fall-Out 558
Table 129: CDG Therapeutics’Included Peptide Drug Pipeline in Oncology and Competitive Fall-Out 564
Table 130: Celecure’s Included Peptide Drug Pipeline in Oncology and Competitive Fall-Out 567
Table 131: Celldex Therapeutics’Included Peptide Drug Pipeline in Oncology and Competitive Fall-Out 570
Table 132: Chemokine Therapeutics’Included Peptide Drug Pipeline in Oncology and Competitive Fall-Out 575
Table 133: Cleveland BioLabs’Included Peptide Drug Pipeline in Oncology and Competitive Fall-Out 579
Table 134: Clinuvel’s Included Peptide Drug Pipeline in Oncology and Competitive Fall-Out 582
Table 135: Compugen’s Included Peptide Drug Pipeline in Oncology and Competitive Fall-Out 585
Table 136: Curaxis’Included Peptide Drug Pipeline in Oncology and Competitive Fall-Out 589
Table 137: Cyclacel’s Included Peptide Drug Pipeline in Oncology and Competitive Fall-Out 593
Table 138: Daiichi Sankyo’s Included Peptide Drug Pipeline in Oncology and Competitive Fall-Out 596
Table 139: Dendreon’s Included Peptide Drug Pipeline in Oncology and Competitive Fall-Out 600
Table 140: Diatos’Included Peptide Drug Pipeline in Oncology and Competitive Fall-Out 605
Table 141: Digna Biotech’s Included Peptide Drug Pipeline in Oncology and Competitive Fall-Out 609
Table 142: Dongkook Pharm’s Included Peptide Drug Pipeline in Oncology and Competitive Fall-Out 613
Table 143: Eli Lilly’s Included Peptide Drug Pipeline in Oncology and Competitive Fall-Out 617
Table 144: Endo Pharmaceuticals’Included Peptide Drug Pipeline in Oncology and Competitive Fall-Out 622
Table 145: Enkam Pharmaceuticals’Included Peptide Drug Pipeline in Oncology and Competitive Fall-Out 626
Table 146: EntreMed’s Included Peptide Drug Pipeline in Oncology and Competitive Fall-Out 630
Table 147: Esperance Pharmaceuticals’Included Peptide Drug Pipeline in Oncology and Competitive Fall-Out 635
Table 148: Galena Biopharma’s Included Peptide Drug Pipeline in Oncology and Competitive Fall-Out 642
Table 149: Generex’s Included Peptide Drug Pipeline in Oncology and Competitive Fall-Out 646
Table 150: GENova Biotherapeutics’Included Peptide Drug Pipeline in Oncology and Competitive Fall-Out 649
Table 151: Genovax’s Included Peptide Drug Pipeline in Oncology and Competitive Fall-Out 653
Table 152: GlaxoSmithKline’s Included Peptide Drug Pipeline in Oncology and Competitive Fall-Out 658
Table 153: Gliknik’s Included Peptide Drug Pipeline in Oncology and Competitive Fall-Out 662
Table 154: GP Pharm’s Included Peptide Drug Pipeline in Oncology and Competitive Fall-Out 666
Table 155: Gryphon Therapeutics’Included Peptide Drug Pipeline in Oncology and Competitive Fall-Out 671
Table 156: Hoffmann-La Roche’s Included Peptide Drug Pipeline in Oncology and Competitive Fall-Out 675
Table 157: ImmunoCellular Therapeutics’Included Peptide Drug Pipeline in Oncology and Competitive Fall-Out 679
Table 158: Immunotope’s Included Peptide Drug Pipeline in Oncology and Competitive Fall-Out 683
Table 159: ImmuPharma’s Included Peptide Drug Pipeline in Oncology and Competitive Fall-Out 688
Table 160: Innovive’s Included Peptide Drug Pipeline in Oncology and Competitive Fall-Out 693
Table 161: ISA Pharmaceuticals’Included Peptide Drug Pipeline in Oncology and Competitive Fall-Out 697
Table 162: Johnson & Johnson’s Included Peptide Drug Pipeline in Oncology and Competitive Fall-Out 702
Table 163: Karyon-CTT’s Included Peptide Drug Pipeline in Oncology and Competitive Fall-Out 707
Table 164: Lee’s Pharmaceutical’s Included Peptide Drug Pipeline in Oncology and Competitive Fall-Out 710
Table 165: Marillion Pharmaceuticals’Included Peptide Drug Pipeline in Oncology and Competitive Fall-Out 713
Table 166: MBiotec’s Included Peptide Drug Pipeline in Oncology and Competitive Fall-Out 717
Table 167: Meda’s Included Peptide Drug Pipeline in Oncology and Competitive Fall-Out 721
Table 168: Mediolanum’s Included Peptide Drug Pipeline in Oncology and Competitive Fall-Out 726
Table 169: MolMed’s Included Peptide Drug Pipeline in Oncology and Competitive Fall-Out 730
Table 170: Nektar Therapeutics’Included Peptide Drug Pipeline in Oncology and Competitive Fall-Out 735
Table 171: Nemod Biotherapeutics’Included Peptide Drug Pipeline in Oncology and Competitive Fall-Out 740
Table 172: Neurobiological Technologies’Included Peptide Drug Pipeline in Oncology and Competitive Fall-Out 744
Table 173: Nidus Laboratories’Included Peptide Drug Pipeline in Oncology and Competitive Fall-Out 748
Table 174: Non-industrial source’s Included Peptide Drug Pipeline in Oncology and Competitive Fall-Out 754
Table 175: Novartis’Included Peptide Drug Pipeline in Oncology and Competitive Fall-Out 762
Table 176: NPS Pharmaceuticals’Included Peptide Drug Pipeline in Oncology and Competitive Fall-Out 766
Table 177: OncoTherapy Science’s Included Peptide Drug Pipeline in Oncology and Competitive Fall-Out 769
Table 178: Oncothyreon’s Included Peptide Drug Pipeline in Oncology and Competitive Fall-Out 774
Table 179: Pepscan Therapeutics’Included Peptide Drug Pipeline in Oncology and Competitive Fall-Out 779
Table 180: Peptagen’s Included Peptide Drug Pipeline in Oncology and Competitive Fall-Out 783
Table 181: PepTx’s Included Peptide Drug Pipeline in Oncology and Competitive Fall-Out 786
Table 182: PharmaGap’s Included Peptide Drug Pipeline in Oncology and Competitive Fall-Out 791
Table 183: Pharmexa’s Included Peptide Drug Pipeline in Oncology and Competitive Fall-Out 796
Table 184: Protagonist’s Included Peptide Drug Pipeline in Oncology and Competitive Fall-Out 800
Table 185: Q Chip’s Included Peptide Drug Pipeline in Oncology and Competitive Fall-Out 804
Table 186: QLT’s Included Peptide Drug Pipeline in Oncology and Competitive Fall-Out 809
Table 187: Raptor Pharmaceutical’s Included Peptide Drug Pipeline in Oncology and Competitive Fall-Out 813
Table 188: Receptor BioLogix’s Included Peptide Drug Pipeline in Oncology and Competitive Fall-Out 818
Table 189: Sanofi-Aventis’Included Peptide Drug Pipeline in Oncology and Competitive Fall-Out 822
Table 190: SciClone Pharmaceuticals’Included Peptide Drug Pipeline in Oncology and Competitive Fall-Out 825
Table 191: Serometrix’s Included Peptide Drug Pipeline in Oncology and Competitive Fall-Out 829
Table 192: Shire’s Included Peptide Drug Pipeline in Oncology and Competitive Fall-Out 833
Table 193: Soligenix’s Included Peptide Drug Pipeline in Oncology and Competitive Fall-Out 838
Table 194: Spectrum Pharmaceuticals’Included Peptide Drug Pipeline in Oncology and Competitive Fall-Out 842
Table 195: Thallion Pharmaceuticals’Included Peptide Drug Pipeline in Oncology and Competitive Fall-Out 845
Table 196: Therion Biologics’Included Peptide Drug Pipeline in Oncology and Competitive Fall-Out 849
Table 197: Theryte’s Included Peptide Drug Pipeline in Oncology and Competitive Fall-Out 852
Table 198: Tigris Pharmaceuticals’Included Peptide Drug Pipeline in Oncology and Competitive Fall-Out 856
Table 199: Unigene’s Included Peptide Drug Pipeline in Oncology and Competitive Fall-Out 860
Table 200: United Biomedical’s Included Peptide Drug Pipeline in Oncology and Competitive Fall-Out 864
Table 201: Vaxil BioTherapeutics’Included Peptide Drug Pipeline in Oncology and Competitive Fall-Out 868
Table 202: Vaxon Biotech’s Included Peptide Drug Pipeline in Oncology and Competitive Fall-Out 873
Table 203: VaxOnco’s Included Peptide Drug Pipeline in Oncology and Competitive Fall-Out 878
Table 204: Wilex’s Included Peptide Drug Pipeline in Oncology and Competitive Fall-Out 883
Table 205: Xigen’s Included Peptide Drug Pipeline in Oncology and Competitive Fall-Out 887
Table 206: Zelos Therapeutics’Included Peptide Drug Pipeline in Oncology and Competitive Fall-Out 890
Table 207: Zensun’s Included Peptide Drug Pipeline in Oncology and Competitive Fall-Out 893

This report includes 104 companies (Incl. Out of Business ones) plus their collaborators:
7TM Pharma
Abbott
Acceleron Pharma
AEterna Zentaris
Affymax
Aileron Therapeutics
Allostera
Allosterix
Ambrilia Biopharma
Anchor Therapeutics
AngioChem
Angstrom Pharmaceuticals
AplaGen Biopharmaceuticals
ApopLogic Pharmaceuticals
Ardana
AstraZeneca
Attenuon
AVI BioPharma
Baxter International
Biokine Therapeutics
Bristol-Myers Squibb
CanBas
Cancer Advances
Cancer Innovations
Cancer Research Technology
CDG Therapeutics
Celecure
Celldex Therapeutics
Chemokine Therapeutics
Cleveland BioLabs
Clinuvel
Compugen
Curaxis
Cyclacel
Daiichi Sankyo
Dendreon
Diatos
Digna Biotech
Dongkook Pharm
Eli Lilly
Endo Pharmaceuticals
Enkam Pharmaceuticals
EntreMed
Esperance Pharmaceuticals
Galena Biopharma
Generex
GENova Biotherapeutics
Genovax
GlaxoSmithKline
Gliknik
GP Pharm
Gryphon Therapeutics
Hoffmann-La Roche
ImmunoCellular Therapeutics
Immunotope
ImmuPharma
Innovive
ISA Pharmaceuticals
Johnson & Johnson
Karyon-CTT
Lee’s Pharmaceutical
Marillion Pharmaceuticals
MBiotec
Meda
Mediolanum
MolMed
Nektar Therapeutics
Nemod Biotherapeutics
Neurobiological Technologies
Nidus Laboratories
Non-industrial source
Novartis
NPS Pharmaceuticals
OncoTherapy Science
Oncothyreon
Pepscan Therapeutics
Peptagen
PepTx
PharmaGap
Pharmexa
Protagonist
Q Chip
QLT
Raptor Pharmaceutical
Receptor BioLogix
Sanofi-Aventis
SciClone Pharmaceuticals
Serometrix
Shire
Soligenix
Spectrum Pharmaceuticals
Thallion Pharmaceuticals
Therion Biologics
Theryte
Tigris Pharmaceuticals
Unigene
United Biomedical
Vaxil BioTherapeutics
Vaxon Biotech
VaxOnco
Wilex
Xigen
Zelos Therapeutics
Zensun
This report includes 152 peptide drugs in cancer. From Ceased to Marketed. Some examples are:
A6
abarelix
ABT-510
AEZS-108
afamelanotide
angiopep+paclitaxel
CBP-501
corticorelin acetate
deslorelin
E-75
emepepimut-S
goserelin
GV-1001
GX-301
histrelin
imMucin
IPP-204106
ISA-P53-01
leuprolide
leuprolide acetate
MDX-1379
NAFB001
netupitant
OTS-102
ozarelix
pasireotide
pasireotide LAR
rindopepimut
romurtide
sotatercept
thymalfasin
tigapotide triflutate
TM-30339
VX-001

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Commercializing Peptides in Cancer: The Faster Route to Consider Your Options and Position of Others.
    To find out more about Commercializing Peptides in Cancer: The Faster Route to Consider Your Options and Position of Others, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Commercializing Peptides in Cancer: The Faster Route to Consider Your Options and Position of Others is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Cancer Highlights' category:


Competitive Outlook on Apoptosis in Oncology
Cancer cells frequently and possibly invariably possess apoptotic defects. In this context, apoptotic pathways provide exciting molecular targets for new therapeutic agents to specifically promote apoptosis of cancer cells. Learn More


Cancer Vaccines: Aim and Shoot
This report aims to analyze the current and future potential of cancer vaccines by examining key fundamentals across the entire pipeline of cancer vaccine drug candidates. Learn More

Other selected research from the 'Oncology' category:


Breast Cancer - Therapeutic And Competitive Insights
Gain insight into the current challenges and commercial opportunities associated with breast cancer therapy. Learn More


Triple Analysis: Leukemia, Lymphoma and Cancer Vaccines
This triple analysis focuses on cancer drug development strategies in both Leukemia and Lymphoma and by the mechanism/target/effect of Cancer Vaccines. Learn More

Other selected research from the 'Biologicals' category:


Peptides in Oncology Drug Pipeline Update
BioSeeker Group have identified 340 companies plus partners who are today developing 356 peptide drugs in 778 developmental projects in cancer across 252 different targets. In addition, there are 4 suspended drugs and another 148 drugs where development has been ceased. Learn More


Cancer Antibodies: Drug Target Atlas and Competitive Outlook
This report is a new and unique way of stratifying and analyzing the global antibody pipeline in cancer towards personalized medicine and presents actionable analysis Learn More